China's medical products administrator granted North China Pharmaceutical (SHA:600812) subsidiary North China Pharmaceutical Hebei Huamin Pharmaceutical marketing approval for its ceftoranil product, according to a Wednesday filing with the Shanghai bourse.
The drug is a cephalosporin antibiotic and is an effective treatment for community-acquired respiratory infections and other diseases such as superficial and deep skin infections, abscesses, pharyngitis and laryngitis, tonsillitis, bronchitis, pneumonia, and other infections, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments